PDCD1 and cancer: Therefore, to understand the resistance mechanisms to immunotherapy and to design rational immunotherapies in cancer with diminished adverse events, it is necessary to delineate the unappreciated mechanisms of PD-1/PD-L1 axis targeted therapy.